Acute LymphocyticLymphoblastic Leukemia Drugs Market Competitive Environment and Higher Growth Rate with Fore - openPR
ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Slightly above 62% of Erytech Pharma's investor base is looking to short. The analysis of current outlook of investing in Erytech Pharma SA suggests that many traders are alarmed regarding Erytech Pharma's prospects. Erytech Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Erytech Pharma SA. Many technical investors use Erytech Pharma SA stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Erytech |
Acute LymphocyticLymphoblastic Leukemia Drugs Market Competitive Environment and Higher Growth Rate with Fore openPR
Read at news.google.com
Erytech Pharma Fundamental Analysis
We analyze Erytech Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Erytech Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Erytech Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Erytech Pharma is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Erytech Pharma SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Erytech Pharma stock to make a market-neutral strategy. Peer analysis of Erytech Pharma could also be used in its relative valuation, which is a method of valuing Erytech Pharma by comparing valuation metrics with similar companies.
Peers
Erytech Pharma Related Equities
SRZN | Surrozen | 19.37 | ||||
XRTX | XORTX Therapeutics | 4.96 | ||||
ATXI | Avenue Therapeutics | 4.37 | ||||
IKNA | Ikena Oncology | 2.37 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
ADXN | Addex Therapeutics | 1.04 | ||||
SNGX | Soligenix | 0.60 | ||||
MOLN | Molecular Partners | 0.17 | ||||
NTRB | Nutriband | 1.03 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
GNFT | Genfit | 1.41 | ||||
ARMP | Armata Pharmaceuticals | 2.13 | ||||
HCWB | HCW Biologics | 6.00 | ||||
XCUR | Exicure | 7.81 | ||||
APM | Aptorum Group | 8.45 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |